Future research should focus on the determination of AMFE efficacy using relevant animal models, such as transgenic mice expressing human amyloid precursor protein and presenilin 1 mutations, to check its impact on AD-related neuropathology and cognitive decline. This evidence concerns the gene PSEN1 and Mental deterioration.